Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 12 Apr 2023
Reach Neuro receives FDA breakthrough device designation for device to restore arm and hand movement to chronic stroke patients
10 April 2023 - Reach Neuro's Avantis device delivers small electrical impulses to the spinal cord to help stroke survivors ...
Posted by Michael Wonder on 11 Apr 2023
ICER publishes 2023 research protocol for assessing unsupported price increases on prescription drugs
11 April 2023 - Annual unsupported price increase report to be published on December 12. ...
Posted by Michael Wonder on 11 Apr 2023
Cancer drug shortages are creating dire circumstances for some patients
11 April 2023 - Robert Landfair, 76, was diagnosed with Stage 4 prostate cancer in 2018. ...
Posted by Michael Wonder on 11 Apr 2023
Abortion ruling could undermine the FDA’s drug approval authority
10 April 2023 - Legal scholars say the ruling by a Texas judge, if upheld, could spur disputes over many medications ...
Posted by Michael Wonder on 11 Apr 2023
How big pharma games the system — and keeps drugs prices high
11 April 2023 - Layers of market protections and courtroom tricks keep competitors off the market far longer than rules intended, ...
Posted by Michael Wonder on 11 Apr 2023
PHARMAC funds second treatment for spinal muscular atrophy
11 April 2023 - PHARMAC has announced the funding of risdiplam (Evrysdi) for people with the rare genetic disorder spinal muscular ...
Posted by Michael Wonder on 11 Apr 2023
RegenxBio receives FDA fast track designation for RGX-202, a novel gene therapy candidate for the treatment of Duchenne muscular dystrophy
11 April 2023 - RGX-202 is a potential one-time AAV therapeutic for the treatment of Duchenne and includes an optimised transgene ...
Posted by Michael Wonder on 11 Apr 2023
Health technology assessment policy and methods review consultation
11 April 2023 - The first round of public consultation for the HTA Review is open. Submissions will be accepted ...
Posted by Michael Wonder on 11 Apr 2023
New life saving medicines
11 April 2023 - The Australian Government has added the two medicines, Kanuma (sebelipase alfa) and Cerdelga (eliglustat) to the Life ...
Posted by Michael Wonder on 10 Apr 2023
Health care regulators’ outdated thinking will cost American ives
10 April 2023 - In a matter of months, ChatGPT has radically altered our nation’s views on artificial intelligence—uprooting old ...
Posted by Michael Wonder on 10 Apr 2023
COVID-19 vaccine safety report (6 April 2023)
6 April 2023 - To 2 April 2023, more than 44 million doses of Comirnaty (Pfizer) mRNA vaccines have been administered in ...
Posted by Michael Wonder on 10 Apr 2023
Cheaper medicines for graft versus host disease, chronic rhinosinusitis and oesophageal cancer
10 April 2023 - For the first time Jakavi (ruxolitinib) will be listed for the treatment of patients with either acute ...
Posted by Michael Wonder on 08 Apr 2023
Accord BioPharma announces US FDA acceptance of biologics license application for proposed biosimilar trastuzumab HLX02
5 April 2023 - The biosimilar for Herceptin seeks to treat several forms of HER2 cancer. ...
Posted by Michael Wonder on 08 Apr 2023
Federal judge stays FDA abortion pill approval, gives Biden administration time to appeal
7 April 2023 - A federal judge in Texas on Friday stayed the FDA’s approval of the abortion pill mifepristone, ...
Posted by Michael Wonder on 08 Apr 2023
NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals
6 April 2023 - Ground breaking commercial deals for the anti-cancer medicine olaparib have paved the way for hundreds to benefit ...